NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-CD-19-001 from the NIH Guide for Grants and Contracts
Notice NOT-AA-19-010 from the NIH Guide for Grants and Contracts
Notice NOT-AG-19-005 from the NIH Guide for Grants and Contracts
Notice NOT-AG-19-004 from the NIH Guide for Grants and Contracts
Notice NOT-GM-19-014 from the NIH Guide for Grants and Contracts
Notice NOT-AT-19-023 from the NIH Guide for Grants and Contracts
Notice NOT-OD-19-070 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-ES-19-001 from the NIH Guide for Grants and Contracts. Chemical modifications of protein, DNA and RNA nucleoside moieties play critical roles in regulating gene expression. Emerging evidence suggests RNA modifications have substantive roles in multiple basic biological processes. Epitranscriptomics can be defined as the aggregate suite of functional biochemical modifications to the transcriptome within a cell. Recent studies in yeast, Drosophila, rodent and human models demonstrate that stressors can induce RNA modifications, with specific reprogramming of some regulatory RNAs. The NIEHS seeks to solicit innovative, mechanistic research applications that are focused on how environmental exposures are associated and involved with the functional activities of RNA modifications and pathways that may be modified or misregulated, associated with adverse health outcomes and/or be useful as biomarkers of exposure and/or exposure-induced pathologies. The study of functional chemical RNA modification has identified important emerging roles in cellular regulation and gene expression. However, the impact of environmental exposures on functional RNA modifications has been relatively understudied and may present a new mechanism for enhanced understanding the relationships between exposures and the development of complex human diseases. The NIEHS will use the R01 mechanism to support hypothesis driven research using approaches that incorporate principles of toxicology with RNA modification biological and/or chemical expertise and utilizes state of the art technologies.
Funding Opportunity RFA-ES-19-002 from the NIH Guide for Grants and Contracts. Chemical modifications of proteins, DNA and RNA nucleoside moieties play critical roles in regulating gene expression. Emerging evidence suggests these RNA modifications (epitranscriptomics) have substantive roles in basic biological processes. Recent studies in yeast, Drosophila and rodent models demonstrate stressors can induce RNA modifications, with specific epitranscriptomic reprogramming of some regulatory RNAs. The purpose of the eFRAMED FOA is to solicit and support R21 applications that propose conducting innovative, high risk, high reward research to enhance our understanding of how environmental exposures impact this layer of cellular regulation.
Notice NOT-GM-19-011 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AI-19-012 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support a national network of research centers for development of effective and comprehensive medical countermeasures applicable to all subsets of the civilian population in the event of radiological or nuclear emergencies. Applications are sought that propose multidisciplinary basic and translational research to support the development of new medical products that will assess, diagnose, mitigate and/or treat the short-, delayed- and long-term consequences of radiation exposure during and following a radiation public health emergency (e.g. a radiological/nuclear terrorist incident or accident). The goals of this FOA are to: 1) develop new techniques and devices to measure radiation exposure in the human body; 2) follow biomarkers of tissue damage and recovery; and 3) further develop existing (e.g. products in clinical use) as well as novel therapies to minimize tissue damage, hasten tissue recovery, restore normal physiological function, and improve survival.
Funding Opportunity RFA-ES-19-005 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits Phase I (R43) and Fast-track (R44) Small Business Innovative Research (SBIR) grant applications from small business concerns (SBCs) in collaboration with environmental science researchers to develop novel tools, activities, or materials to build environmental health literacy for a variety of groups, including community members, health care and public health professionals, educators, and students of all ages.
Funding Opportunity RFA-ES-19-006 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits Phase I (R43) and Fast-track (R44) Small Business Technology Transfer (STTR) grant applications from small business concerns (SBCs) in collaboration with environmental science researchers to develop novel tools, activities, or materials to build environmental health literacy for a variety of groups, including community members, health care and public health professionals, educators, and students of all ages.
Notice NOT-FD-19-005 from the NIH Guide for Grants and Contracts
Notice NOT-DA-19-022 from the NIH Guide for Grants and Contracts
Notice NOT-AI-19-040 from the NIH Guide for Grants and Contracts
Notice NOT-AA-19-009 from the NIH Guide for Grants and Contracts
Notice NOT-HL-19-679 from the NIH Guide for Grants and Contracts
Notice NOT-FD-19-004 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-FD-19-010 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity is to support the research and development necessary to advance non-invasive (e.g., quantitative tomography-based) technologies, including the development of apparatus, methods, study designs, and methods of data analysis, to characterize and compare the rate and extent to which a topically applied drug becomes available at or near a site of action within the skin. The expectation is that the funded work will produce an accurate, sensitive and reproducible approach that rapidly measures the (relative) amount of drug present in the skin at a series of depths below the skin surface, which can be utilized to monitor the cutaneous pharmacokinetics (PK) of the drug at selected depths (e.g., in the epidermis and dermis) by repeated, serial measurements over time. The intent is to support the eventual development of an alternative, scientifically valid, cutaneous PK-based approach that can be used to efficiently demonstrate the bioequivalence (BE) of topical products.